131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML

Older patients (pts) with relapsed or refractory acute myeloid leukemia (AML) have poor outcomes which have not improved over time. Only about 30% of AML pts aged 65 and older are offered treatment and the vast majority are not eligible for curative allogeneic hematopoietic cell transplant (HCT). Age as an independent risk factor for non-relapse mortality (NRM) exists in a continuum. 131I-apamistamab (Iomab-B), an anti-CD45 radioimmunoconjugate, safely delivers targeted radiation, allowing for myeloablation and eradication of leukemic cells.

https://www.astctjournal.org/article/S2666-6367(23)01824-9/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Rajneesh Nath, Stuart Seropian, Boglarka Gyurkocza, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick J. Stiff, Sunil H. Abhyankar, James Foran, Sameem Abedin, George L Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Or Tags: 61 Source Type: research